Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
AST.WS was delisted on the 26th of September, 2017.
37 hedge funds and large institutions have $394K invested in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 10 reducing their positions, and 2 closing their positions.
177% more capital invested
Capital invested by funds: $142K → $394K (+$251K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 38 → 37 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
90% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
+$20.5K |
| 2 |
Goldman Sachs
New York
|
+$546 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TA
Teachers Advisors
New York
|
-$1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$290 |
| 3 |
Morgan Stanley
New York
|
-$61 |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$51 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$7 |
AST.WS Hedge Fund Activity: Q3 2016 in Review
37 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) for Q3 2016, worth a combined $394K — up 177% from $142K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of AST.WS and 1 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 1 added.
The largest buyer was Manatuck Hill Partners, opening a new position worth an estimated $20.5K. The largest seller was Teachers Advisors, exiting entirely with an estimated $1K sold.
- 37 institutional investors held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) as of Q3 2016, down from 38 in Q2 2016.
- Funds reported $394K of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) stock for Q3 2016, up 177% quarter-over-quarter.
- 1 fund opened new Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) positions in Q3 2016 and 2 closed out, a net change of -1 holder.
- The largest Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) buyer in Q3 2016 was Manatuck Hill Partners, an estimated $20.5K added.
- The largest Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) seller in Q3 2016 was Teachers Advisors, an estimated $1K sold.
Based on aggregated 13F filings for Q3 2016.